Monday, December 23, 2024
HomeTagsYH003

YH003

Biocytogen/Eucure Biopharma Announce the Completion of First Patient Dosing for Phase II Clinical Trial of YH003 in Australia

Eucure Biopharma, a wholly owned subsidiary of Biocytogen, announced the first patient dosing for a phase II clinical trial of YH003 (anti-CD40 monoclonal antibody,...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics